-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca reports positive Phase 1 dose-escalation data for pan-RAS drug ERAS-0015

PUBT·04/27/2026 20:09:57
Listen to the news
Erasca reports positive Phase 1 dose-escalation data for pan-RAS drug ERAS-0015
  • Erasca released positive preliminary Phase 1 dose-escalation results for pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors, with results already disclosed from ongoing trials in US and China.
  • Data showed meaningful tumor shrinkage signals in KRAS-mutant lung cancer and pancreatic cancer, supporting potential best-in-class positioning in key commercial indications.
  • Safety profile appeared manageable in early testing, with no dose-limiting toxicities reported at data cutoff.
  • Erasca selected 24 mg and 32 mg once-daily doses to carry forward into monotherapy expansion, tightening development focus for next-stage readouts.
  • Company guided to present select monotherapy expansion data plus combination dose-escalation data in H1 2027, including early evidence supporting combination with panitumumab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.